Ads
related to: statins don't increase survivability due to cancer cells research method
Search results
Results From The WOW.Com Content Network
Alternative uses for statins for other health conditions are an ongoing area of research. Effects of statins on inflammation, cancer. Researchers of the current study note that chronic ...
IL-33 signals the body to produce other immune system cells when an injury or infection occurs. ... In Demehri’s research it is apparently due to its anti-inflammatory effects, but this may not ...
Clinical studies have been conducted on the use of statins in dementia, [215] lung cancer, [216] nuclear cataracts, [217] hypertension, [218] [219] and prostate cancer [220] and breast cancer. [221] There is no high quality evidence that statins are useful for pneumonia . [ 222 ]
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.
HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, official symbol HMGCR) is the rate-controlling enzyme (NADH-dependent, EC 1.1.1.88; NADPH-dependent, EC 1.1.1.34) of the mevalonate pathway, the metabolic pathway that produces cholesterol and other isoprenoids.
The pharmacological results from cerivastatin show that it is the most active HMG-CoA-reductase inhibitor among reported statins. Due to its high enzyme affinity, it would seem to offer ultra-low dose therapy in the microgram range. However, due to its relatively severe adverse effects in comparison to other statins, its market use was ...
For premium support please call: 800-290-4726 more ways to reach us
In 2020, Cancer Cell made a number of changes to increase diversity and inclusion of underrepresented minorities in cancer research and oncology. In June 2020, the journal announced the new members of its advisory board (previously editorial board), which includes a higher representation of female scientists (>40%) and physicians (~50%) and ...